The RAS is a novel target in the study of diabetes, and clinical trials have indicated that ARBs, such as valsartan, may exert some of their clinical effects through an influence on adipose tissue. We studied the effect of valsartan on adipokine genes resistin (rstn) and fasting-induced adipose factor (fiaf) using obese and diabetic ob/ob mice. In addition to visceral and subcutaneous fat, rstn and fiaf mRNA levels were also measured in several other tissues known to express these adipokines, including the pituitary, cerebral cortex and hypothalamus. The significant findings were that (a) fiaf gene expression was elevated two-to fourfold in visceral and subcutaneous fat from ob/ob mice, compared with lean controls; (b) the increase in fiaf mRNA in subcutaneous, but not visceral, fat from ob/ob mice was returned to lean control levels following 2 weeks of valsartan treatment; (c) fiaf expression was reduced in the hypothalamus, but not in the cortex or pituitary, of ob/ob mice; (d) rstn expression was greatly reduced in visceral fat from ob/ob mice, compared with lean controls, but this was unaffected by valsartan; and (e) rstn expression was unchanged in all other tissues from ob/ob mice, with or without valsartan treatment.
Introduction
Obesity is firmly implicated as a risk factor for T2DM and hypertension. Research into the underlying molecular mechanisms is extensive, and the search for therapeutic drugs an important goal. The RAS is one such target. The inhibition of the RAS, for example through blockade of the ANG II receptor type 1 (AT1), is effective in reducing the incidence of T2DM especially in hypertensive patients. [1] [2] [3] It is also likely that ANG II is implicated in the pathogenesis of hypertension as well as in insulin resistance. 4 The ideal clinical management of a syndrome that includes obesity, hypertension and insulin resistance (the metabolic syndrome) would involve antihypertensive drugs that could also improve the abnormal metabolism associated with obesity.
Clinical trials have indicated that ACE inhibitors and ARBs, such as valsartan, play a role in the prevention of T2DM. [5] [6] [7] [8] [9] Furthermore, a recent meta-analysis comparing various antihypertensive agents showed that ACE inhibitors and ARBs were least likely to be associated with the development of new-onset T2DM. 10 Various mechanisms have been suggested for the salutary effect of these drugs on glucose homeostasis, 11, 12 but an intriguing view is that ANG II receptor blockers such as valsartan have direct effects on secretion in hypertensive, 18, 19 and normal Sprague-Dawley rats. 20 Plasma levels of another adipokine, adiponectin, are increased in losartan-treated type 1 diabetic patients, 21 in cardesartan-and valsartan-treated hypertensives, 22 and in valsartan-treated patients with T2DM. 23 Thus an important question is whether the therapeutic benefits of valsartan might accrue, at least partially, from its effects on the expression of adipose tissue genes. As noted, there is evidence that two clinically important adipokine genes -leptin and adiponectin -are regulated by valsartan. These two adipokines are members of a large array of secretory factors now known to be produced by adipose tissue. [24] [25] [26] Many of these could play important roles in the pathophysiology of the metabolic syndrome. Based upon its known effects on leptin and adiponectin, we hypothesised that valsartan may also regulate the expression of other adipokines such as resistin and FIAF (fasting-induced adipose factor), which have been linked to obesity and insulin resistance. Resistin, in particular, has attracted controversy as a possible link between obesity and insulin resistance, and there is evidence for both sides of this discussion. 27, 28 Also, FIAF, an angiopoietin-like protein, is implicated in the metabolic syndrome 29 and in insulin resistance. 30, 31 Due to the growing evidence that rstn and fiaf may play a crucial role in the development of T2DM through their effect on insulin signalling and energy homeostasis, and because ARBs are reported to exert direct effects on adipose tissue, we designed experiments to investigate the effect of valsartan treatment on adipose rstn and fiaf mRNA levels. We chose to explore the ob/ob mouse as a model system because these animals are obese and diabetic. We demonstrated previously that ob/ob mice express rstn in several tissues, including subcutaneous and visceral fat. 32 Fiaf expression is also present in mouse fat. 33, 34 In addition, because these two adipokines are expressed in several non-adipose tissues, such as brain, 35 we quantified gene expression in pituitary, cerebral cortex and hypothalamus.
Materials and methods
Male mice (C57BL/6 lean and obese B6.V-Lep ob /J) were obtained from the Jackson Laboratory (Bar Harbor, Maine, USA) at 6 weeks of age, maintained under a photoperiod of 12 h light:12 h darkness (lights on at 0700 h) and given free access to Purina Rat Chow and drinking water. The mice were used for the experiment at 13 weeks of age. Valsartan was dissolved in a mixture of DMSO, 0.1 N sodium hydroxide and water. For example, 10 mg of valsartan dissolved readily in 800 μL DMSO, 200 μL 0.1 N sodium hydroxide and 2.1 ml water. This solution was loaded into Alzet osmotic minipumps (Alzet; Model 1002; 0.25 μL/h; 14 days) to provide a dose of 1 mg/kg/day as previously described. 4, 36 This dose of valsartan was shown to increase insulin sensitivity and glucose uptake in skeletal muscle, and to improve adipocyte differentiation in diabetic mice.
Ob/ob mice were anaesthetised using isoflurane/oxygen (4% oxygen) and a small dorsal incision was made behind the head to permit the formation of a subscapular pocket into which the minipumps were introduced. Incisions were closed with wound clips. Both the lean and ob/ob control animals received a sham-surgery alone. Animals were monitored for a period of 14 days and then on the day of sacrifice (by decapitation) various tissues (epididymal (visceral) and subcutaneous adipose tissues, cerebral cortex, hypothalamus and whole pituitary gland) were dissected and frozen at -70°C. The experimental protocol was reviewed and approved by the Dalhousie University Committee on Laboratory Animals.
RNA isolation and realtime RT-PCR
Total RNA was isolated from adipose tissue using Trizol (Invitrogen; Burlington, Ont., Canada), and from the remainder of the tissues using the Total RNA kit following the DNase protocol (Sigma; Mississauga, Ont., Canada) according to the manufacturers instructions. RNA (1 mg) was reverse transcribed using Superscript III reverse transcriptase (Invitrogen) in a total volume of 20 μL according to the manufacturer's instructions. PCR amplification was carried out using previously published primers and Taqman™ probes for rstn, fiaf and cyclophilin 37 in a total volume of 32 mL using Platinum Quantitative PCR SuperMix-UDG (Invitrogen). Amplification was carried out following 5 min heat activation at 95°C, followed by 45 cycles consisting of 95°C for 20 s and 60-61°C for 60 s. Samples were analysed in duplicate and relative copy numbers were obtained based on standard curve values. Reactions were normalised to cyclophilin mRNA, and data expressed as a percentage of the control ±SEM. Statistical analysis was performed using ANOVA followed by the Newman-Keuls multiple comparisons test. Significance was set at p<0.05.
Results

Valsartan failed to modify body weights of ob/ob mice
The dose of valsartan used in this work (1 mg/kg/day; 14 days) was without effect on body weights of the ob/ob mice (ob/ob controls, no drug; 53.4±2.7 g vs. ob/ob treated; 59.4±0.8 g; n=5 per group; NS). Body weights of the lean control mice were 30.5±0.7 g (p<0.001 vs. ob/ob mice; n=5).
No effect of valsartan on resistin (rstn) gene expression
Rstn mRNA levels in subcutaneous adipose tissue were similar between the lean and ob/ob groups, and valsartan treatment had no significant effect on rstn expression ( Figure 1B) . In contrast, rstn expression was significantly lower in visceral adipose tissue of ob/ob mice when compared with lean controls (-90%, p<0.001), but valsartan treatment had no effect on rstn expression in ob/ob mice ( Figure 1A ). There were no differences in rstn mRNA in the hypothalamus, cortex and pituitary between any of the mouse groups, nor was there any effect of valsartan in these tissues from ob/ob mice ( Figure 2 ).
Valsartan reduced fiaf gene expression in subcutaneous, but not visceral, fat
Fiaf gene expression was almost fourfold higher (p<0.01) in the subcutaneous fat of leptin-deficient ob/ob mice compared with lean controls ( Figure 1D ). Treatment of ob/ob mice with valsartan led to a significant reduction in fiaf mRNA, equal to the values detected in lean mice. In contrast, although fiaf mRNA was twofold higher (p<0.001) in visceral fat of ob/ob mice relative to the lean controls, valsartan failed to modify fiaf expression ( Figure 1C ). We also saw an effect of obesity on hypothalamic fiaf gene expression; i.e. fiaf mRNA was significantly lower in ob/ob mice relative to the lean controls (p<0.05) ( Figure 2D ), but valsartan failed to restore its expression to lean control levels. Pituitary and cortical fiaf expression was unchanged in all groups.
Discussion
The significant findings of the present study were that (a) fiaf gene expression was elevated two-to fourfold in Figure 1 . The effects of valsartan treatment on rstn and fiaf mRNA in visceral and subcutaneous fat tissue of ob/ob mice. Ob/ob mice were implanted with Alzet minipumps that released valsartan (1 mg/kg/day) over a period of 14 days. When compared with lean control mice, rstn expression was markedly reduced in visceral fat in both untreated and valsartan-treated ob/ob mice ( Figure 1A ). There was no significant effect of obesity or valsartan on rstn mRNA in subcutaneous fat ( Figure 1B) . Fiaf expression was significantly up-regulated in both visceral and subcutaneous fat obtained from ob/ob mice ( Figure 1C and 1D ). Valsartan treatment reversed this increase in subcutaneous, but not visceral, adipose tissue. Values are expressed as a percentage of the values in the lean mice ±SEM (n=4-5); ** p<0.01; *** p<0.001.
visceral and subcutaneous fat from ob/ob mice, compared with lean controls; (b) the increase in fiaf mRNA in subcutaneous, but not visceral, fat from ob/ob mice was returned to lean control levels following 2 weeks of valsartan treatment; (c) fiaf expression was reduced in hypothalamus, but not cortex or pituitary, of ob/ob mice; (d) rstn expression was greatly reduced in visceral fat from ob/ob mice, compared with lean controls, but this was unaffected by valsartan; and (e) rstn expression was not significantly modified by obesity or valsartan in any of the other tissues analysed (visceral or subcutaneous fat, hypothalamus, cortex, and pituitary gland).
The detection of an increase in adipose fiaf mRNA in ob/ob mice is consistent with a previous report, 38 which described a three-to fourfold increase in PGAR mRNA in visceral fat from ob/ob mice. PGAR was subsequently identified as fiaf but is also known as angiopoietin-like protein, 4, 39 and was shown by us to be expressed in mouse cortex, hypothalamus, pituitary and adipose tissue. 34 In the context of the present work it is noteworthy that adipose fiaf expression was robustly up-regulated by fasting in mouse and rat tissue. In contrast, Dutton and Trayhurn reported a fasting-induced increase in fiaf mRNA in mouse liver and skeletal muscle, but not in adipose tissue. 41 The reason for this discrepant finding is unclear, though these latter authors speculated that the effect of fasting may be mouse strain dependent. Nonetheless, in our hands fastinginduced up-regulation of fiaf expression in adipose tissue could reflect the reduced secretion of leptin known to occur in fasted animals. By implication, the total absence of leptin in ob/ob mice should also increase fiaf expression, and this was seen by us in the present work. Previous studies showed that leptin did not affect fiaf expression in mouse adipocytes in vitro. 41 However, evidence for an inhibitory effect of leptin on fiaf mRNA levels in adipose tissue was reported. 38 These authors demonstrated that food restriction-induced increases in fiaf expression could be prevented by co-injection of leptin over the 5 days of food Figure 2 . The effects of valsartan treatment on rstn and fiaf mRNA in hypothalamus, cerebral cortex and pituitary gland tissue of ob/ob mice. Ob/ob mice were implanted with Alzet minipumps that released valsartan (1 mg/kg/day) over a period of 14 days. There was no effect of treatment, or obesity, on rstn mRNA levels in any tissue (Figure 2A-2C) . Fiaf expression was similarly unaffected in pituitary and cortex, but was significantly reduced in hypothalamus from both ob/ob and ob/ob + valsartan mice ( Figure 2D ). Values are expressed as a percentage of the values in the lean mice ±SEM (n=3-5). * p<0.05; ** p<0.01. restriction. Therefore, since valsartan treatment of ob/ob mice actually restored fiaf mRNA levels to those seen in lean mice, leptin cannot be involved in the effects of valsartan on adipose fiaf expression. It remains to be determined whether leptin treatment might also reduce fiaf expression in ob/ob mice. Finally, the specific inhibitory effect of valsartan on fiaf expression in subcutaneous, but not visceral, fat in ob/ob mice is intriguing. Gene array studies have revealed significant differences between gene expression in subcutaneous and visceral fat, 42 and it may be that differences in metabolic and functional properties of adipose tissue depots could offer important clinical insights. 43 Valsartan treatment appears to be one approach to discriminate between visceral and subcutaneous production of the adipokine FIAF.
Previously ARBs have been shown to positively impact energy metabolism, which might be mediated at least in part through their modulatory effects on serum adipokine levels (e.g. leptin and adiponectin), but could also be due to other effects on adipose tissue. For example, valsartan therapy was found to modestly, but significantly, reduce circulating leptin levels in obese hypertensive patients, 17 while simultaneously increasing serum adiponectin. 44, 45 In contrast, the related drug, telmisartan, increased leptin serum levels in both hypertensive and type II diabetic patients, 46 whereas losartan had no effect on leptin secretion in patients with hypertension. 47, 48 The selective deletion of angiotensinogen in mice also led to similar changes in circulating leptin and adiponectin concentrations, although the most striking hormonal change measured was the significant reductions detected in serum resistin levels relative to wild-type mice. 49 Further, this was associated with significant reductions in bodyweight, total fat mass and adiposity (fat mass expressed as a percentage of body weight) relative to control mice. 49, 50 Moreover these effects were the opposite of those found when angiotensinogen was overexpressed, which led to increased adipose tissue mass and elevated leptin levels, although serum resistin or adiponectin concentrations were unaffected. 49, 50 The overexpression of angiotensinogen also led to adipocyte hypertrophy and appeared to stimulate lipogenesis and triglyceride synthesis in both murine and human adipocytes, 51 but paradoxically was associated with adipocyte hypoplasia in vivo. 50 These findings not only implicate the RAS in the normal control of adipose tissue mass and growth, but disruption of this system also appears to confer beneficial reductions in bodyweight in addition to modifying circulating adipokine concentrations. Perhaps of equal relevance is evidence that adipose tissue produces angiotensinogen which is released into the circulation and promotes local adipose tissue differentiation as well as weight regulation. 36, 49, 50, 52 In fact, there is now good evidence for a local RAS within adipose tissue that appears to regulate adipose tissue growth, metabolism and differentiation. 14, 40 These observations are consistent with the identification of angiotensin II receptor expression in human and rodent adipocytes. 15, 16 The RAS also appears to be a critical modulator of triglyceride metabolism and cellular differentiation in adipose tissue, 50 where it significantly impacts adipokine gene regulation. 49 We saw no effect of valsartan treatment on body weight of ob/ob mice, and this confirms the previous report from Shiuchi et al. 4 Blockade of the angiotensin receptor (AT1) with valsartan was previously reported to reduce adipose tissue weight and adipocyte size in mice, but paradoxically appeared to increase adipocyte differentiation. 36 However, these effects were only detectable in the KKAY mouse strain of diabetes and obesity, and not in healthy C57BL6 mice, suggesting that the effects of RAS blockade are at least partially dependent on genetic background. 36 Losartan treatment (2 weeks) was also found to slow, but not stop, bodyweight gain in Sprague-Dawley rats, and this was also associated with a disproportionately larger reduction in epididymal adipose tissue mass. 53 However, a similar experiment using valsartan had no effect on bodyweight in the same strain of rats, although it did reduce adipocyte cell volume. 52 Therefore, the lack of any significant bodyweight changes in leptin-deficient ob/ob mice treated with valsartan is not totally unexpected, but may reflect the unique hormonal and genetic profile of this obese animal model .Also, it is possible that subtle changes in adipose tissue characteristics (e.g. adipocyte size) may have occurred, but these were not analysed in these investigations.
The lack of effect of valsartan on rstn expression was unexpected, although we confirmed that rstn mRNA was significantly lower in visceral fat of adult ob/ob mice relative to lean controls. 54, 55 It is known that disruption of endogenous angiotensinogen expression in mice was not only associated with significant changes in circulating leptin and adiponectin, but that one of the most striking reductions detected was in serum resistin levels. 50 Although Losartan, an ARB similar to valsartan, was reported to have no effect on circulating resistin levels in hypertensive patients following an 8-week treatment, 48 it was capable of preventing the increases induced by a hyperinsulinaemic euglycaemic clamp in healthy subjects. 56 However, these studies only measured circulating adipokine levels, and changes in adipokine mRNA were not analysed. Further, the reported reductions in circulating adipokines following ARB treatment may reflect changes in adipose tissue mass directly, and might occur independently of any gene expression changes. However some ARBs, including losartan, telmisartan and candesartan, but not valsartan, were shown to act as bona fide PPARγ ligands in vitro, a critical nuclear receptor implicated in the regulation of adipogenesis and normal adipokine gene regulation. 38, 57 The failure of valsartan to have a significant effect on gene expression may also reflect potential genetic differences in the mouse strains used in these studies, namely ob/ob and C57BL/6. The role of centrally acting, peripherally derived adipokines in glucose metabolism and energy homeostasis is now well established. 58 We have added to the complexity of this system by providing evidence for brain and pituitary production of several adipokines, more appropriately termed cephalokines. 35 The precise role(s) that these factors play in energy homeostasis is yet to be determined, but the known presence of a RAS in brain suggested that they may be affected by valsartan treatment. Although we failed to detect any significant adipokine gene expression changes following valsartan treatment, with the exception of the reduced fiaf mRNA in subcutaneous adipose tissue, this may in part reflect the animal model (ob/ob mice) as well as the type of AT1-blocker (valsartan) used. However, complex feedback mechanisms may also have prevented gene expression changes from occurring. Further, our analysis of adipokine gene expression alone does not necessarily reflect circulating adipokine levels. For example, we and others found that rstn mRNA was significantly lower in visceral adipose tissue of ob/ob mice, 32, 54, 55, 59 yet plasma resistin concentrations have been reported to be significantly elevated. 55, 59 This paradoxical pattern of expression might reflect a negative feedback regulatory mechanism in which high serum resistin levels help prevent a further increase in rstn gene expression, although resistin stability and removal may also be altered in the obese state, 55 and other tissues (e.g. pituitary and brain) might also contribute to the overall circulating pool of resistin. Similarly, leptin has been shown to inhibit rstn gene expression. 55, 59 Thus the failure of valsartan to modify rstn gene expression could be the consequence of using a leptin-deficient mouse model. Future studies in alternative models of obesity and diabetes would be usefuIn summary, previous reports indicate that ARBs, such as valsartan, appear to have a significant effect on metabolic and adipocyte function, although the mechanisms through which these events are occurring remains poorly understood. In the present investigations valsartan failed to have any significant effect on rstn gene expression in any of the tissues analysed, but significantly reduced fiaf gene expression in subcutaneous adipose tissue of ob/ob mice. These studies do not preclude any changes having occurred in circulating adipokine levels, which should be evaluated in future investigations, but also suggest that other animal models, such as diabetic and diet-induced obese mice, should be examined.
